Chongqing Daxin Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 8 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 June 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3000291692 |
| Molecule | Regulators | Docs |
|---|---|---|
| Daptomycin | US FDA | 2 |
| Lovastatin | US FDA | 2 |
| Mycophenolic Acid | US FDA | 2 |
| Mevastatin | US FDA | 1 |
| Mycophenolate Mofetil | US FDA | 1 |
| Sirolimus | US FDA | 1 |
| Tobramycin | US FDA | 1 |
| Vancomycin | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 2 | None |
| US FDA | None | 1 |
Choose your molecules and target markets. Chongqing Daxin Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free